{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:00:32Z","timestamp":1792807232419,"version":"4.5.0"},"reference-count":37,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>In general, racial and ethnic differences exist in antipsychotic prescription practices. However, little is known about such differences between individual long-acting injectable (LAI) antipsychotic formulations, specifically. This study's primary objective was to determine racial and ethnic differences among LAI antipsychotic use. Secondary objectives were to identify if discontinuation rates differed between agents and by race or ethnicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>International Classification of Diseases, 10th edition (ICD-10) codes were used to identify patients with schizophrenia and related disorders (18-64 years) who received an LAI antipsychotic between 2016 and 2020 using Merative Multi-State Medicaid databases. Using National Drug Code numbers for LAI antipsychotics, pharmacy claims were identified and data analyzed. Cochran-Mantel-Haenszel tests and odds ratio estimators were used to investigate conditional association between race or ethnicity and medication, while controlling for age, sex, health plan, and prescription year. Kaplan-Meier survival curves were examined, and stratified log-rank tests were conducted to compare the time until discontinuation distributions by race or ethnicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The analysis included 37\u2009712 patients. Blacks received an LAI first-generation antipsychotic more often than Whites (OR: 1.64, 95% CI: [1.56, 1.73], Hispanics (OR: 1.46, 95% CI: [1.21, 1.75]) and others (OR: 1.44, 95% CI: [1.20, 1.73]). Aside from fluphenazine decanoate showing earlier discontinuation rates for Whites over Blacks (P = .02), no significant differences in discontinuation across race or ethnicity were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Despite no significant differences in second-generation antipsychotic LAI discontinuation rates between Blacks and other racial or ethnic groups, Blacks received second-generation antipsychotic LAIs significantly less often than other groups. Further studies are needed to determine why differences may be occurring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2023.08.183","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T17:10:14Z","timestamp":1691428214000},"page":"183-189","source":"Crossref","is-referenced-by-count":5,"title":["Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data"],"prefix":"10.9740","volume":"13","author":[{"given":"Joshua","family":"Caballero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Xu","sequence":"additional","affiliation":[{"name":"2 PhD Student, Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Hall","sequence":"additional","affiliation":[{"name":"3 Professor and Director, Statistical Consulting Center, Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyan","family":"Chen","sequence":"additional","affiliation":[{"name":"4 Senior Academic Professional, Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Young","sequence":"additional","affiliation":[{"name":"5 Department Head and Kroger Professor, Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"issue":"(4)","key":"2023080806202062200_i2168-9709-13-4-183-b01","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5498\/wjp.v4.i4.133","article-title":"Racial disparities in psychotic disorder diagnosis: A review of empirical literature","volume":"4","author":"Schwartz","year":"2014","journal-title":"World J Psychiatry"},{"issue":"(6)","key":"2023080806202062200_i2168-9709-13-4-183-b02","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archpsyc.60.6.637","article-title":"Diagnostic patterns in Latino, African American, and European American psychiatric patients","volume":"60","author":"Minsky","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"(8)","key":"2023080806202062200_i2168-9709-13-4-183-b03","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.biopsych.2005.04.034","article-title":"The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)","volume":"58","author":"Kessler","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"(11)","key":"2023080806202062200_i2168-9709-13-4-183-b04","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1017\/S0033291706008191","article-title":"Annual prevalence of diagnosed schizophrenia in the USA: A claims data analysis approach","volume":"36","author":"Wu","year":"2006","journal-title":"Psychol Med"},{"issue":"(4)","key":"2023080806202062200_i2168-9709-13-4-183-b05","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jphs.12027","article-title":"Estimating the direct and indirect costs for community-dwelling patients with schizophrenia","volume":"4","author":"Desai","year":"2013","journal-title":"J Pharm Health Serv Res"},{"issue":"(3)","key":"2023080806202062200_i2168-9709-13-4-183-b06","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1176\/appi.ps.201700459","article-title":"Decision making about pathways through care for racially and ethnically diverse young adults with early psychosis","volume":"70","author":"Myers","year":"2019","journal-title":"Psychiatr Serv"},{"issue":"(5)","key":"2023080806202062200_i2168-9709-13-4-183-b07","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10488-012-0429-5","article-title":"African American families' expectations and intentions for mental health services","volume":"40","author":"Thompson","year":"2013","journal-title":"Adm Policy Ment Health"},{"issue":"(10)","key":"2023080806202062200_i2168-9709-13-4-183-b08","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"(15)","key":"2023080806202062200_i2168-9709-13-4-183-b09","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.3390\/jcm11154530","article-title":"Second-generation antipsychotics' effectiveness and tolerability: A review of real-world studies in patients with schizophrenia and related disorders","volume":"11","author":"Fabrazzo","year":"2022","journal-title":"J Clin Med"},{"issue":"(5)","key":"2023080806202062200_i2168-9709-13-4-183-b10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","article-title":"Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: A systematic review and meta-analysis","volume":"35","author":"Lin","year":"2021","journal-title":"CNS Drugs"},{"issue":"(03)","key":"2023080806202062200_i2168-9709-13-4-183-b11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"2023080806202062200_i2168-9709-13-4-183-b12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-244X-10-89","article-title":"Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder","volume":"10","author":"Stauffer","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"(04)","key":"2023080806202062200_i2168-9709-13-4-183-b13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4088\/JCP.11m07161","article-title":"Race and long-acting antipsychotic prescription at a community mental health center","volume":"73","author":"Aggarwal","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2023080806202062200_i2168-9709-13-4-183-b14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S251812","article-title":"Patients' preference for long-acting injectable versus oral antipsychotics in schizophrenia: Results from the patient-reported medication preference questionnaire","volume":"14","author":"Blackwood","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2023080806202062200_i2168-9709-13-4-183-b15","volume-title":"IBM MarketScan Research Databases for life sciences researchers [white paper]","author":"Hansen"},{"issue":"(11)","key":"2023080806202062200_i2168-9709-13-4-183-b16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/cer-2018-0068","article-title":"Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder","volume":"7","author":"Yan","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"(1)","key":"2023080806202062200_i2168-9709-13-4-183-b17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/03007995.2017.1395733","article-title":"All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics","volume":"34","author":"Yan","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"(10)","key":"2023080806202062200_i2168-9709-13-4-183-b18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40263-021-00849-2","article-title":"Real-world outcomes and costs following 6 months of treatment with the long-acting injectable (LAI) aripiprazole lauroxil for the treatment of schizophrenia","volume":"35","author":"Lauriello","year":"2021","journal-title":"CNS Drugs"},{"key":"2023080806202062200_i2168-9709-13-4-183-b19","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics [Internet].\nInternational Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis codes [cited 2022 Nov 1]. Available from: https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm.htm"},{"key":"2023080806202062200_i2168-9709-13-4-183-b20","unstructured":"NDCList.com [Internet].\nNational Drug Codes List [cited 2022 Nov 1]. Available from: https:\/\/ndclist.com\/."},{"key":"2023080806202062200_i2168-9709-13-4-183-b21","unstructured":"Accessdata.fda.gov [Internet].\nUS Food and Drug Administration [cited 2022 Nov 1]. Available from: www.accessdata.fda.gov"},{"issue":"(9)","key":"2023080806202062200_i2168-9709-13-4-183-b22","first-page":"754","article-title":"Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge","volume":"21","author":"Marcus","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"(1)","key":"2023080806202062200_i2168-9709-13-4-183-b23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12888-022-03895-2","article-title":"Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"(7)","key":"2023080806202062200_i2168-9709-13-4-183-b24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4088\/JCP.v62n07a08","article-title":"Adherence assessments and the use of depot antipsychotics in patients with schizophrenia","volume":"62","author":"Valenstein","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"(4)","key":"2023080806202062200_i2168-9709-13-4-183-b25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1176\/appi.ajp.159.4.567","article-title":"Racial disparities in antipsychotic prescription patterns for patients with schizophrenia","volume":"159","author":"Kuno","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"Suppl 4","key":"2023080806202062200_i2168-9709-13-4-183-b26","first-page":"15","article-title":"Review of incidence studies of tardive dyskinesia associated with typical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"2023080806202062200_i2168-9709-13-4-183-b27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2023080806202062200_i2168-9709-13-4-183-b28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2147\/PPA.S59371","article-title":"Approaches to improve adherence to pharmacotherapy in patients with schizophrenia","volume":"8","author":"Shuler","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"(5)","key":"2023080806202062200_i2168-9709-13-4-183-b29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1037\/a0039346","article-title":"Using the theory of planned behavior to improve treatment adherence in Mexican Americans with schizophrenia","volume":"83","author":"Kopelowicz","year":"2015","journal-title":"J Consult Clin Psychology"},{"issue":"(1)","key":"2023080806202062200_i2168-9709-13-4-183-b30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/pop.2018.0206","article-title":"Patient-reported experiences in discussing prescribed medications with a health care provider: Evidence for racial\/ethnic disparities in a large health care delivery system","volume":"23","author":"Chung","year":"2020","journal-title":"Popul Health Manag"},{"issue":"(10)","key":"2023080806202062200_i2168-9709-13-4-183-b31","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4088\/JCP.v69n1004","article-title":"A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: Depot versus oral","volume":"69","author":"Patel","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"(4)","key":"2023080806202062200_i2168-9709-13-4-183-b32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JCP.0000000000001225","article-title":"Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"40","author":"Lindenmayer","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"(6)","key":"2023080806202062200_i2168-9709-13-4-183-b33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4088\/JCP.13m08946","article-title":"The challenge of offering long-acting antipsychotic therapies: A preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia","volume":"76","author":"Weiden","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"(7)","key":"2023080806202062200_i2168-9709-13-4-183-b34","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.pec.2019.02.003","article-title":"Minority patient preferences, barriers, and facilitators for shared decision-making with health care providers in the USA: A systematic review","volume":"102","author":"Perez Jolles","year":"2019","journal-title":"Patient Educ Couns"},{"issue":"(4)","key":"2023080806202062200_i2168-9709-13-4-183-b35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jamapsychiatry.2017.4585","article-title":"Effectiveness of the DECIDE interventions on shared decision making and perceived quality of care in behavioral health with multicultural patients: A randomized clinical trial","volume":"75","author":"Alegria","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"(2)","key":"2023080806202062200_i2168-9709-13-4-183-b36","doi-asserted-by":"crossref","first-page":"e0263264","DOI":"10.1371\/journal.pone.0263264","article-title":"Development of a computerized intervention to improve health literacy in older Hispanics with type 2 diabetes using a pharmacist supervised comprehensive medication management","volume":"17","author":"Caballero","year":"2022","journal-title":"PLoS One"},{"issue":"(7)","key":"2023080806202062200_i2168-9709-13-4-183-b37","first-page":"399","article-title":"Factors associated with adherence to the HEDIS quality measure in Medicaid patients with schizophrenia","volume":"9","author":"Lafeuille","year":"2016","journal-title":"Am Health Drug Benefits"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/13\/4\/183\/3245742\/i2168-9709-13-4-183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/13\/4\/183\/3245742\/i2168-9709-13-4-183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:59Z","timestamp":1731687839000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/13\/4\/article-p183.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,7]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2023.08.183","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}